<DOC>
	<DOCNO>NCT00328601</DOCNO>
	<brief_summary>The primary objective trial determine optimal dose orally ( tablet ) administer thioctic acid treatment symptom diabetic polyneuropathy ( dPNP ) . It expect least one three dosage test ( 600 , 1200 , 1800 mg tablet ) orally administer thioctic acid improve symptom dPNP compare placebo . Secondary objective evaluation variable pertinent dPNP , safety , tolerability .</brief_summary>
	<brief_title>Assessment Efficacy Safety Thioctic Acid Oral Treatment Symptomatic Diabetic Neuropathy ( SYDNEY 2 )</brief_title>
	<detailed_description>Following screen visit , patient receive placebo oral 7 day . Eligible patient chronic symptom randomly assign one 4 treatment group treat trial medication 5 week .</detailed_description>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>1 . Diabetes mellitus ( Type I II ) , define American Diabetes Association , 1997 , last 1 year . 2 . Patient must symmetric sensorymotor peripheral polyneuropathy least stage 2 attributable diabetes mellitus follow thorough evaluation cause neuropathy . 3 . HbA1C &lt; 10 % . 4 . TSS &gt; 7.5 point . 5 . NISLL &gt; 2 point . 6 . Pain sensation ( accord pinprick sensitivity test ) absent decrease ( NIS item 35 1 ) . 7 . Age range : 18 74 year . Inclusion criterion prior randomisation 8 . The TSS must &gt; 5 point 9 . The TSS range ( maximum TSS minus minimum TSS runin phase ) must less 3 point avoid inclusion patient rapidly oscillate symptom . 10 . At least 1 4 symptom TSS must occur continuously last 3 month . 11 . Lack compliance , i.e . 85 % 115 % ( Accordingly , 6 daily dos take 7 daily dos schedule Phase A would acceptable ) . Lack suitability trial : 1 . Proximal asymmetric neuropathy , cranial neuropathy , truncal radiculopathy , diabetic plexopathies , acute active mononeuropathy ( include cranial neuropathy , postherpes neuralgias , etc . ) , exception carpal tunnel syndrome ( CTS ) tardy ulnar neuropathy ( TUN ) . 2 . Neuropathy cause diabetes mellitus might interfere assessment severity dPNP . 3 . Other neurologic disease may produce weakness , sensory loss , autonomic symptom test abnormality . 4 . Myopathy cause . 5 . Peripheral vascular disease severe enough cause intermittent claudication ischemic ulcer limb ischemia . 6 . Patients proliferate retinopathy require immediately therapy impend blindness . 7 . Psychiatric , psychological , behavioural symptom would interfere patient 's ability participate trial . 8 . Patients active neoplastic disease except basal cell carcinoma . 9 . Patients atrial fibrillation unless control stabilised medication . 10 . Patients clinically significant cardiac , pulmonary , gastrointestinal , haematological , endocrine disease ( diabetes ) may confound interpretation study result prevent patient completing study . 11 . Patients organ transplant kind . 12 . Patients significant hepatic renal disease ( ASAT , ALAT GGT &gt; 2 time normal , serum creatinine &gt; 1.8 mg/dL ( &gt; 159 mmol/l ) males &gt; 1.6 mg/dL ( &gt; 141 mmol/l ) female ) . 13 . Patients recent history ( within last 12 month ) drug alcohol abuse . 14 . Use investigational drug ( participation clinical trial ) within last 1 month . 15 . History severe anaphylactic reaction drug , sulfur biologic product . 16 . Recent ( within last 3 month ) ketoacidosis hypoglycaemia , necessitate hospital admission . 17 . Antioxidant therapy ( vitamin E &gt; 400 IU , C &gt; 200 mg , betaCarotene &gt; 30 mg ) pentoxyphylline within last 1 month start trial . 18 . Use thioctic acid ( &gt; 50 mg ) , even primrose oil gammalinolenic acid contain substance within last 3 month . 19 . Continued use medication list section 6.2.3 . 20 . Bilateral sural nerve biopsy . 21 . Existing foot ulcer . Safety concern : 22 . Pregnant lactating female : Pregnancy evidence positive bhCGtest screen visit test perform study site demand , woman childbearing potential use adequate contraception . 23 . History allergic reaction study medication excipients . Administrative reason : 24 . Informed Consent sign patient complete competence cooperate . 25 . Any language barrier affect adequate understanding . 26 . Anticipated nonavailability study visits/procedures . 27 . Vulnerable subject ( person keep detention )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>